Gelteq
Customizable ingestible gels for partner-branded health and animal-health products.
Something off on this page? Send us feedback.
Profile
Formulates customizable ingestible gels for partner-branded pharmaceutical, consumer-health and animal-health products, earning product revenue when manufactured gels are delivered. Its small, collaboration-based model relies on contract manufacturers, licensees and distributors while drug candidates remain subject to clinical and regulatory validation.
Develops customizable ingestible gels for pharmaceutical, consumer-health and animal-health partners. Its matrix can be formulated to mask taste, support set dosing, alter viscosity and release characteristics, and carry pharmaceuticals, nutraceuticals, proteins, vitamins, minerals and plant compounds. Offerings span pet gels, pharmaceutical and over-the-counter gels, and nutraceutical and sports-nutrition gels, including the SportsGel brand.
Generates product revenue when partner-branded, white-label or customized gels are manufactured and delivered. Manufacturing, sales and distribution rely on third parties, while regulated human and veterinary drug programs require clinical results and regulatory approval. Commercial activity is concentrated in the United States, Australia and China/East Asia; the company operates as a single development-and-testing segment.
Company facts
Key statistics
Year to date −33.9% · Average volume (30d) 69.3K
Analysts
No analyst consensus on record.
Earnings
Not reported.
Financial highlights
| 7 quarters | Q4 FY22 | Q4 FY23 | Q3 FY24 | Q4 FY24 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $105.7K | −$1 | $0 | $0 | $64.0K | $64.0K | |
| Gross profit | $105.7K | −$1 | $0 | $0 | $64.0K | $64.0K | |
| Operating income | −$746.1K | −$597.0K | −$7.2M | −$692.5K | −$1.3M | −$1.3M | |
| Net income | −$886.0K | −$679.1K | −$521.1K | −$811.8K | −$1.3M | −$1.3M | |
| Diluted EPS | −$0.09 | $0.00 | $0.00 | $0.00 | −$0.13 | −$0.13 | |
| Gross margin | 100.0% | — | — | — | 100.0% | 100.0% | |
| Operating margin | -705.9% | — | — | — | -1,986.0% | -1,986.0% |
Balance sheet, Dec 31, 2025Cash & short-term investments $6.7K · Total debt $3.7M · Total assets $14.4M · Shareholders' equity $10.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.18M · Float 3.64M · 39.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Nathan J. Givoni · officer: Chief Executive Officer | 657.1K | 7.16% | Form 4 | Mar 18, 2026 |
| Bradley Glenn Karp · officer: Head of Sales and Marketing | 500.0K | 5.45% | Form 4 | Mar 18, 2026 |
| Simon H. Szewach · director | 338.2K | 3.68% | Form 4 | Mar 18, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Lexaria Bioscience
Oral drug-delivery platform rival for pharma and consumer licensees.
- Rani
Oral-biologics platform rival for injection-replacement partnerships.
- Lifeward
Successor owner of the filing-named POD oral protein platform.
- Entera Bio
Oral peptide platform rival in metabolic and endocrine drug programs.
- Nutriband
Transdermal drug-delivery alternative for pharmaceutical development partners.
- Insulet
Commercial insulin-delivery alternative to oral diabetes formulations.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gelteq | $0.5277 | −5.00% | $5.1M | — | — | 39.9 | — |
| Lexaria Bioscience | $10.30 | −1.03% | $17.1M | — | — | 88.2 | −88.5% |
| Rani | $0.8703 | +3.59% | $54.9M | — | — | 11.3 | — |
| Lifeward | $7.47 | +0.13% | $12.0M | — | — | 0.6 | +15.7% |
| Entera Bio | $3.03 | −0.33% | $149.3M | — | — | — | — |
| Nutriband | $4.46 | −0.22% | $54.2M | — | — | 30.1 | −32.5% |
| Insulet | $145.31 | +0.11% | $10.05B | 27.1 | 21.0 | 3.3 | +23.5% |
| Median | 27.1 | 21.0 | 11.3 | −8.4% |